Unprecedented Early-Stage Cancer Detection Presented at AACR 2026
Dxcover Highlights Liquid Biopsy Platform Performance in Multiple Settings Glasgow, UK, April 2, 2026 — Dxcover, a global leader in…
Dxcover is a clinical stage liquid biopsy company developing tests for the early detection of multiple cancers, when treatment has a better chance to impact outcomes.
The company has pioneered the early detection and identification of cancer employing infrared spectroscopy of circulating pan-omic biomarkers. The company has generated compelling clinical data with high accuracy detection of Stage I and Stage II cancers. Dxcover is based in Scotland, United Kingdom and is establishing operations in the USA.
Award Winning Co.
Dxcover Secures CE-IVDR Certification
Key Milestone Signals Readiness for Regulated Diagnostic Deployment Glasgow, UK, March 3, 2026 — Dxcover, a global leader in AI-enabled…
New Blood Test Helps GPs Manage Brain Scan Delays, Brings Field Forward
GLASGOW, UK, February 13, 2026 — Dxcover, a global leader in innovative AI-enabled technologies, today announced the availability of its…
Dxcover Strengthens Leadership with World-Class Scientific Advisors and Board Members
Date: 04 August 2025 – GLASGOW, Scotland – Dxcover, a clinical-stage oncology diagnostics company developing and commercializing its Multiomic Spectral…
Dxcover launches US operations to commercialize its AI-powered multiomic cancer detection test
Date: 24 June 2025 Opens U.S. headquarters in Nashville – a leading healthcare and life sciences hub Building the foundation…
Dxcover Announces Global Presentation Of First Real-World Evidence Demonstrating That Increased Tumour Size Is Associated With Higher Mortality In Patients With Brain Cancer
GLASGOW, Scotland (April 30, 2025) Dxcover Limited, a clinical-stage diagnostics company pioneering its multiomic spectral analysis (MOSA-Dx™) for early detection…
Dxcover Accelerates Growth With New Funding Round and Strengthens The Leadership Team
February 03, 2025 09:00 AM GMT New capital raise from existing investors, as well as new investors, Macmillan Cancer Support…
Dxcover names first US Scientific Advisory Board Member
Luke Pike MD, DPhil, Radiation Oncologist, joins Dxcover Scientific Advisory Board to advise the company on brain cancer diagnostic early…
Dxcover Recognised for Scientific Excellence at ADLM2024
Distinguished Abstract Award to be presented Wednesday July 31 at Academy of Diagnostics & Laboratory Medicine Annual Meeting in Chicago.…
Head of Commercial Development UK & EU Joins the Team
We are thrilled to announce that Abigail Lishman has joined our team as the Head of Commercial Development in the…
#GBMDay in the US
Dxcover Ltd joins in recognizing July 17 2024 as #GBMDay in the US Company establishing US operations in Nashville TN…
May is Brain Cancer Awareness Month
May 29, 2024 GLASGOW, Scotland–Dxcover Limited, a clinical-stage diagnostics company pioneering its multi-omic spectral analysis (MOSA) for early detection of…
CEO Professor Matt Baker Featured Panelist at EIE24 Meeting
May 13, 2024 | GLASGOW, Scotland Dxcover Limited, a clinical-stage diagnostics company pioneering its multi-omic spectral analysis (MOSA) for early…
Dxcover to Present its Colorectal Cancer and Advanced Adenoma Study at AACR 2024
Dxcover invited to present its CREATE-2 clinical trial for the early detection of colorectal cancer and advanced adenoma at the…
Experts come together to improve brain tumour diagnosis in Scotland
5th Feburary 2024 Glasgow-based Dxcover Ltd. are developing a diagnostic tool to detect brain tumours, and they are one of…
Dxcover Announces Three New Clinical Trials for Brain, Colorectal and Lung Cancer Detection
The trials will utilize the Dxcover Liquid Biopsy Test to detect cancer at its earliest signs Glasgow, Scotland, January 9,…
Dxcover To Present at BIOTECH SHOWCASE™ 2024
Prof. Matthew Baker to present data on detection of early-stage tumors across multiple cancers. Glasgow, Scotland, December 20, 2023 …
Dxcover Announces Updates to Executive Leadership Team
Founder and CTO Prof. Matthew Baker named Chief Executive Officer Chief Data Scientist Dr David Palmer named Chief Technical Officer…
Dxcover Discuss Liquid Biopsy Platform with 360Dx
CEO, Mark Hegarty, and CTO, Matthew Baker, were recently interviewed by 360Dx about Dxcover’s ground breaking blood test for Brain…
Dxcover Awarded First Prize for Poster at ESMO 2023
Prize awarded in the Innovative Diagnostics Tools category supporting the groundbreaking potential of the Dxcover Multi-Omic Spectral Analysis in Early…
Early Detection of Multiple Cancers Study Published in British Journal of Cancer
Benefits of the multi-omic spectral analysis approach highlight the significant potential of the Dxcover Platform for early detection of cancer.…
Dxcover Announces Expansion of Its Leadership Team
Ron Andrews Joins Company as Non-Executive Chair Stacy Chick Named US Commercial & Business Development Advisor and Stuart McRoberts Named…
Liquid Biopsy Platform for Early Colorectal Cancer Detection at AACR 2023
Rapid blood test sensitive to advanced adenomas could improve patient prognosis and ultimately reduce mortality. Dxcover Limited, a clinical-stage diagnostics…
Dxcover Raises $11.9m in Series A and Grant Funding to Accelerate Liquid Biopsy to Market
Enables CE Marking of blood test for brain cancer and advances colorectal cancer development. Glasgow, Scotland, February 1, 2023 Dxcover…
Dxcover Secures Grant from the European Innovation Council
Grant enables pivotal multi-centre study for CE Marking of Dxcover Brain Cancer Liquid Biopsy. Dxcover Limited, a clinical stage diagnostics…
Effective Early Detection of Pancreatic Cancer Using Infrared Spectroscopy
Study published in Cancers demonstrates how simple, minimally invasive and accurate approaches can represent a powerful aid in earlier detection…
Dxcover Launches Infrared Platform: Ground-breaking technology for faster sample analysis
Dublin, Ireland June 20, 2022 Dxcover Limited, a diagnostics company developing spectroscopic liquid biopsy technology for early detection of multiple…
Dxcover Presents Data on Benefits of Spectroscopic Liquid Biopsy at ASCO
Dxcover test could have a significant impact on early detection of cancer, vital for improved survival and quality of life…
Dxcover to release new data on early detection liquid biopsy for multiple cancer types at 2022 ASCO
Dxcover Limited, a clinical stage diagnostics company developing its spectroscopic biopsy technology for early detection of multiple cancers, today announced…
Dxcover to release data on early detection of multiple-solid tumors at AACR 2022 Annual Meeting
Data highlight high sensitivity of novel infrared spectroscopy approach for stage I disease SCOTLAND, UK., March 29, 2022 Dxcover Limited,…
Dxcover advances fast-track cancer diagnosis
Cancer diagnostics company, Dxcover Limited, has published its latest data from clinical studies on earlier detection of aggressive cancers. The…
Dxcover secures US patent for game-changing cancer diagnostic devices
Dxcover Limited, developer of liquid biopsies for the early detection of cancer, has secured US patents for its groundbreaking Dxcover®…
Dxcover® Secures ISO 13485 Certification
Dxcover Limited, developer of liquid biopsies for the early detection of cancer, has secured ISO 13485:2016 certification for its Quality…
SelectScience® Highlight Dxcover Game Changing Blood Test
An editorial article from SelectScience was published on 26th January 2022, with an interview with Dxcover CEO Mark Hegarty. The…
Dr Paul Brennan joins the Dxcover Scientific Advisory Board
Dxcover® are delighted to announce the appointment of Dr Paul Brennan to their Scientific Advisory Board (SAB). Dr Brennan is…
Early brain cancer detection breakthrough for Dxcover
· Blood test proves ability to identify really small brain tumours and gives hope of earlier detection and improved survival…
The future of cancer diagnostics is now
We were delighted to speak to Health Tech World recently about the future of cancer diagnostics. “Hailed as the future…
Dxcover Limited appoints Operations Director
Dxcover Limited has appointed experienced diagnostics industry professional Dr David Eustace as Operations Director to drive product development, manufacturing, regulatory…
ClinSpec Diagnostics rebrands as Dxcover and targets growth
Luke Pike MD, DPhil, Radiation Oncologist, joins Dxcover Scientific Advisory Board to advise the company on brain cancer diagnostic early…
Cancer diagnostics firm completes £3.5M funding round
ClinSpec Diagnostics Limited (ClinSpec Dx), the Glasgow-based developer of liquid biopsies for early detection of cancer, has reached its round…
ClinSpec Dx receive £2.4m funding boost
Luke Pike MD, DPhil, Radiation Oncologist, joins Dxcover Scientific Advisory Board to advise the company on brain cancer diagnostic early…
The Rt Hon Boris Johnson MP says ClinSpec Diagnostics technology will save lives
The Tech Nation 2020 report on ‘UK Tech for a changing world’ was released this week, looking to overview the…
KPMG Best British Tech Pioneer – ClinSpec Dx shortlisted
ClinSpec Diagnostics are delighted to announce that they were shortlisted as one of the top pioneering technology companies at 2020’s…
ClinSpec Dx are part of Tech Nation!
ClinSpec Diagnostics have been announced as one of the members of the first ever Tech Nation Applied AI cohort! …
Preliminary results from brain cancer study published in Nature Communications
A blood test which could help to accelerate the diagnosis of brain cancer has been developed in research led at…
US and EU patent granted
We are pleased to announce that our base patent has been granted in the USA and the EU, covering our…
Clinspec Dx win the Scottish Life Sciences Innovation award
Clinspec Dx are crowned the winners of Scotland’s Life Sciences Innovation award! There are 7 prestigious awards acknowledging a range…
ClinSpec Diagnostics Spin-out
ClinSpec Diagnostics are delighted to announce the completion of seed investment to spin-out of the University of Strathclyde, following a…
ClinSpec Dx™ win Scottish Edge award and also presented with Higgs special award
Dr. Holly Butler and Dr. Mark Hegarty had the pleasure of presenting to a panel at the Scottish Edge awards.…
ClinSpec Dx™ win the Moonshot award at the Global Game Changers ’18
ClinSpec Dx™ were the recipients of the Moonshot award at the Global Game Changers, which rewards businesses that are striving…
SPEC 2018 conference in Glasgow
The international SPEC 2018 conference was held in Glasgow at the Technology and Innovation Centre from the 10-15th of June.…
ClinSpec Dx co-founder named one of “20 women to watch”
Insider.co.uk this week revealed their latest installment of “20 women to watch in Scotland in 2018”, and named a ClinSpec…
ClinSpec Dx pitch at EIE18
Dr Holly Butler of ClinSpec Dx pitched at 2018’s prestigious Engage, Invest, Exploit (EIE) event, held at the McEwan Hall,…
Evidence of ClinSpec Dx health economic benefit published in British Medical Journal OA
An early health economic assessment of a spectroscopic blood test for the early detection of brain tumours conducted by members…
Top 40 under 40 – The Analytical Scientist
Inventor and Chief Science Officer, Dr Matthew Baker was placed on the top 40 under 40 ran by The Analytical…
ClinSpec Dx installed at Edinburgh’s Western General Hospital
The ClinSpec Dx Triage ID system is now installed at Western General Hospital in Edinburgh, to undergo a new clinical…
Award season for ClinSpec Dx
Autumn was a busy season for ClinSpec Dx; with the Converge Challenge Finals looming, there were also some personal successes…
ClinSpec Dx runners up in Converge Challenge 2017
The Converge Challenge second place prize was awarded to Dr Holly Butler of University of Strathclyde with ClinSpec Dx, a…
Glasgow to host SPEC2018 Conference
The SPEC2018 Conference will take place in the Technology and Innovation Centre of the University of Strathclyde from 10th -…
ClinSpec Dx win Ready, Steady, Pitch! at Converge Challenge 2017
Dr Holly J Butler wins first prize for ClinSpec Dx at the Converge Challenge awards 2017. Read all about it…